Infusion bag of midazolam for intravenous use

US11273100B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11273100-B2
Application numberUS-202016796292-A
CountryUS
Kind codeB2
Filing dateFeb 20, 2020
Priority dateFeb 22, 2019
Publication dateMar 15, 2022
Grant dateMar 15, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.

First claim

Opening claim text (preview).

We claim: 1. A sterile, ready-to-use infusion container comprising a stable, aqueous solution of midazolam comprising: a. midazolam or a pharmaceutically acceptable salt thereof; b. a tonicity adjusting agent; c. a pH adjusting agent; and d. water for injection, wherein the midazolam or pharmaceutically acceptable salt thereof does not adsorb on an innermost layer of the infusion container, the innermost layer is made-up of a cyclo-olefin polymer or a cyclo-olefin co-polymer, and the solution was subjected to terminal sterilization by autoclaving. 2. The sterile, ready-to-use infusion container according to claim 1 , wherein the stable, aqueous solution has a concentration of 0.1 mg/ml to 2.0 mg/ml of midazolam or a base equivalent concentration of a pharmaceutically acceptable salt thereof. 3. The sterile, ready-to-use infusion container according to claim 1 , wherein the stable, aqueous solution has a concentration of 0.5 mg/ml to 1.0 mg/ml of midazolam or a base equivalent concentration of a pharmaceutically acceptable salt thereof. 4. The sterile, ready-to-use infusion container according to claim 1 , wherein the tonicity adjusting agent is sodium chloride. 5. The sterile, ready-to-use infusion container according to claim 1 , wherein the pH of the stable, aqueous solution is 3.0 to 4.5. 6. The sterile, ready-to-use infusion container according to claim 1 , wherein the pH of the stable, aqueous solution is 3.0 to 4.0. 7. The sterile, ready-to-use infusion container according to claim 1 , wherein the pH of the stable, aqueous solution is 3.4±0.2. 8. The sterile, ready-to-use infusion container according to claim 1 , wherein the stable aqueous solution is free of a chelating agent, an antioxidant, a stabilizer, a complexing agent and/or a preservative. 9. The sterile, ready-to-use infusion container according to claim 1 , wherein the container is a rigid, semi-rigid or a flexible container. 10. The sterile, ready-to-use infusion container according to claim 1 , wherein the container is a flexible bag. 11. The sterile, ready-to-use flexible bag according to claim 10 , wherein the wall of the body of the bag comprises at least two layers and wherein the innermost layer is made-up of a material that does not show adsorption of midazolam on its surface. 12. The sterile, ready-to-use flexible bag according to claim 10 , wherein the wall of the body of the flexible infusion bag comprises at least three layers wherein the outermost layer is made-up of polypropylene (PP), middle layer is made-up of linear low density polyethylene (LLDPE), and the innermost layer is made-up of a cyclo-olefin polymer or a cyclo-olefin co-polymer. 13. The sterile, ready-to-use, infusion container according to claim 1 , wherein the container is terminally sterilized. 14. The sterile, ready-to-use, infusion container according to claim 1 , wherein the container is optionally overwrapped by an overwrap pouch covering the filled and sealed infusion container. 15. A sterile, ready-to-use infusion container comprising a stable, aqueous solution of midazolam comprising: a. midazolam or a pharmaceutically acceptable salt thereof; b. a tonicity adjusting agent; c. a pH adjusting agent; and d. water for injection, wherein (i) the aqueous solution of midazolam of a pharmaceutically acceptable salt thereof in the container remains free of any sub-visible particles (Nylon particles) at room temperature for at least 6 months (ii) the innermost layer of the infusion container is made-up of a cyclo-olefin polymer or a cyclo-olefin co-polymer, and (iii) the solution was subjected to terminal sterilization by autoclaving. 16. The sterile, ready-to-use infusion container according to claim 1 , wherein the infusion container is a flexible, multi-layered bag comprising: a, a body filled with about 80 ml to about 500 ml of the stable, aqueous solution of midazolam or a pharmaceutically acceptable salt thereof; and b. one or more tubes fixed to the body of the infusion bag. 17. The sterile, ready-to-use, infusion container according to claim 1 , wherein the container comprises at least two tubes with one of the at least two tubes fixed to the body of the infusion bag, and wherein one of the at least two tubes is fitted to an outlet port which is designed to attach to a sterile infusion set, and another tube is fitted to an inlet port which is designed to receive a sterile fluid which is with or without a medicament other than midazolam. 18. A method of treating a disease or a condition or providing a supportive medication comprising intravenously administering to a patient in need thereof, a stable, aqueous solution of midazolam or a pharmaceutically acceptable salt thereof from an infusion container according to claim 1 . 19. The method according to claim 18 , wherein the disease or condition for treatment or supportive medication is selected from the group consisting of preoperative sedation, anxiolysis, amnesia, for induction of general anaesthesia and before administration of other anaesthetics agents.

Assignees

Inventors

Classifications

  • A61J1/1468Primary

    Containers characterised by specific material properties · CPC title

  • Inorganic compounds · CPC title

  • Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor · CPC title

  • Anaesthetics · CPC title

  • Inlet or outlet ports · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11273100B2 cover?
The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the sa…
Who is the assignee on this patent?
Sun Pharmaceutical Ind Ltd
What technology area does this patent fall under?
Primary CPC classification A61J1/1468. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).